Skip to main content

Table 3 Multivariate analysis of transplant outcomes according to donor type

From: Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT

Outcome

MSD

MUD

Haplo

Reference

HR

95% CI

p

HR

95% CI

p

Acute GvHD grade II–IV

1

1.25

0.73–2.13

0.4

0.99

0.62–1.57

1

Overall chronic GvHD

1

1.84

1.02–3.34

0.04

1.03

0.59–1.79

0.9

NRM

1

1.06

0.47–2.38

0.9

1.16

0.60–2.25

0.7

RI

1

0.78

0.38–1.57

0.5

0.74

0.43–1.28

0.3

LFS

1

0.91

0.54–1.55

0.7

0.91

0.59–1.39

0.7

OS

1

1.05

0.57–1.94

0.9

1.13

0.68–1.86

0.6

GRFS

1

1.02

0.65–1.59

0.9

0.96

0.66–1.4

0.8

  1. GvHD, graft-versus-host disease; HR, hazard ratio; CI, confidence interval; p, p value; NRM, non-relapse mortality; RI, relapse incidence; LFS, leukemia-free survival; OS, overall survival; GRFS, graft-versus-host disease-free, relapse-free survival; MSD, matched sibling donor; MUD, matched unrelated donor; Haplo, haploidentical donor